This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

This study has been completed.
Sponsor:
Collaborators:
Takeda
Sucampo Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Jack DiPalma, University of South Alabama
ClinicalTrials.gov Identifier:
NCT00746395
First received: September 3, 2008
Last updated: November 7, 2016
Last verified: November 2016
September 3, 2008
November 7, 2016
April 2008
September 2008   (Final data collection date for primary outcome measure)
Complete Small Bowel Transit [ Time Frame: 8 hours ]
Percent of subjects with capsule passage through small bowel
Complete Small Bowel Transit [ Time Frame: end of study ]
Complete list of historical versions of study NCT00746395 on ClinicalTrials.gov Archive Site
Small Bowel Transit [ Time Frame: Duration of the test - 8 hours ]
Small bowel transit time
Cleansing preparation [ Time Frame: end of study ]
Not Provided
Not Provided
 
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.

Introduction of small bowel capsule endoscopy made available an unique technique for diagnostic evaluation of the gastrointestinal tract. After esophagogastroduodenoscopy and colonoscopy about 5% of bleeding cases remain unexplained and capsule endoscopy provides small bowel yield. Capsule endoscopy has special application for evaluation of inflammation bowel disease and other small bowel conditions. Several adjuncts are used to enhance the examination by improving cleansing preparation or propulsion. Metoclopramide, tegaserod, simethicone, erythromycin, phosphates and polyethylene glycol (PEG) colon cleansing agents have been tried and some show improved visualization or increased propulsion where more capsules reach to colonic cecum while still recording within the limits of its 8 hour battery. Recently, our group had an observational report of our experience showing that either full bowel cleansing preparation or prokinetics such as metoclopramide or tegaserod enhanced visualization and functioning capsule transit to the colon. Lubiprostone is a novel chloride channel activator that increases intestinal fluid secretion and motility. It is FDA approved and indicated for treatment of chronic idiopathic constipation.

This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy. The FDA approved 24 mcg constipation dose was chosen because other medications used in similar single dose in our pilot studies appear effective.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Inflammatory Bowel Disease
  • Drug: Lubiprostone
    24 mcg oral administration
    Other Name: Amitiza
  • Drug: Placebo
    Oral administration
    Other Name: Sugar pill
  • Active Comparator: lubiprostone 24mcg single dose
    lubiprostone 24mcg single dose po prior to capsule endoscopy
    Intervention: Drug: Lubiprostone
  • Placebo Comparator: Sugar pill
    Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
    Intervention: Drug: Placebo
Hooks SB 3rd, Rutland TJ, Di Palma JA. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. Gastrointest Endosc. 2009 Nov;70(5):942-6. doi: 10.1016/j.gie.2009.04.045. Epub 2009 Jul 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
September 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  • Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea
Sexes Eligible for Study: All
19 Years to 90 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00746395
07-096
No
Not Provided
Not Provided
Jack DiPalma, University of South Alabama
University of South Alabama
  • Takeda
  • Sucampo Pharmaceuticals, Inc.
Principal Investigator: JAck A DiPalma, MD University of South Alabama
University of South Alabama
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP